Download PDF
Semin Respir Crit Care Med 2011; 32(1): 094-101
DOI: 10.1055/s-0031-1272873
© Thieme Medical Publishers

Advances in the Treatment of Small-Cell Lung Cancer

Gregory P. Kalemkerian1
  • 1Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, Michigan
Further Information

Publication History

Publication Date:
15 April 2011 (online)

    Permissions and Reprints

ABSTRACT

Small-cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastatic dissemination and responsiveness to initial therapy. The incidence of SCLC has been declining over the past decade, mainly due to a decreased incidence in men. Positron-emission tomographic (PET) scans appear to improve the accuracy of staging and treatment planning in patients with SCLC. Limited-stage (LS) SCLC is a potentially curable disease, with long-term survival of ~20% when treated with platinum-based chemotherapy plus concurrent thoracic radiation. Hyperfractionated thoracic radiation and prophylactic cranial irradiation (PCI) may significantly improve overall survival in selected patients with LS-SCLC. For patients with extensive-stage (ES) SCLC, survival can be increased with combination chemotherapy, but the disease remains incurable, and long-term survival is rare. The use of PCI has recently been reported to further improve overall survival in ES-SCLC. Several newer cytotoxic agents, such as amrubicin, have promising activity in early clinical trials. Although many potential molecular targets have been identified in preclinical studies of SCLC, molecularly targeted therapy has yet to demonstrate any substantial activity in clinical trials. Nonetheless, future advances in this disease will undoubtedly depend on improvements in our understanding of the molecular mechanisms that drive the proliferation and survival of SCLC cells.

KEYWORDS

Small-cell lung cancer - chemotherapy - prophylactic cranial irradiation

REFERENCES

  • 1 Navada S, Lai P, Schwartz A G, Kalemkerian G P. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results database.  [abstract 7082] J Clin Oncol. 2006;  24 (18 Suppl) 384s
    PubMedSearch in Google Scholar
  • 2 Govindan R, Page N, Morgensztern D et al.. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.  J Clin Oncol. 2006;  24 (28) 4539-4544
    CrossrefPubMedSearch in Google Scholar
  • 3 Zelen M. Keynote address on biostatistics and data retrieval.  Cancer Chemother Rep 3. 1973;  4 (2) 31-42
    PubMedSearch in Google Scholar
  • 4 Goldstraw P, Crowley J J, Chansky K International Association for the Study of Lung Cancer International Staging Committee et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours.  J Thorac Oncol. 2007;  2 (8) 706-714
    CrossrefPubMedSearch in Google Scholar
  • 5 Shepherd F A, Crowley J, Van Houtte P et al.. The IASLC Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer.  J Thorac Oncol. 2007;  2 1067-1077
    CrossrefPubMedSearch in Google Scholar
  • 6 Kalemkerian G P, Akerley W, Downey R J et al.. Small cell lung cancer.  J Natl Compr Canc Netw. 2008;  6 (3) 294-314
    PubMedSearch in Google Scholar
  • 7 Bradley J D, Dehdashti F, Mintun M A, Govindan R, Trinkaus K, Siegel B A. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.  J Clin Oncol. 2004;  22 (16) 3248-3254
    CrossrefPubMedSearch in Google Scholar
  • 8 Brink I, Schumacher T, Mix M et al.. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.  Eur J Nucl Med Mol Imaging. 2004;  31 (12) 1614-1620
    CrossrefPubMedSearch in Google Scholar
  • 9 Hauber H P, Bohuslavizki K H, Lund C H, Fritscher-Ravens A, Meyer A, Pforte A. Positron emission tomography in the staging of small-cell lung cancer : a preliminary study.  Chest. 2001;  119 (3) 950-954
    CrossrefPubMedSearch in Google Scholar
  • 10 Kamel E M, Zwahlen D, Wyss M T, Stumpe K D, von Schulthess G K, Steinert H C. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.  J Nucl Med. 2003;  44 (12) 1911-1917
    PubMedSearch in Google Scholar
  • 11 Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers J S. Can positron emission tomography be used as a staging tool for small-cell lung cancer?.  Clin Lung Cancer. 2008;  9 (1) 30-34
    CrossrefPubMedSearch in Google Scholar
  • 12 Pignon J P, Arriagada R, Ihde D C et al.. A meta-analysis of thoracic radiotherapy for small-cell lung cancer.  N Engl J Med. 1992;  327 (23) 1618-1624
    CrossrefPubMedSearch in Google Scholar
  • 13 Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.  J Clin Oncol. 1992;  10 (6) 890-895
    CrossrefPubMedSearch in Google Scholar
  • 14 Fried D B, Morris D E, Poole C et al.. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.  J Clin Oncol. 2004;  22 (23) 4837-4845
    CrossrefPubMedSearch in Google Scholar
  • 15 Turrisi III A T, Kim K, Blum R et al.. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.  N Engl J Med. 1999;  340 (4) 265-271
    CrossrefPubMedSearch in Google Scholar
  • 16 Bonner J A, Sloan J A, Shanahan T G et al.. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma.  J Clin Oncol. 1999;  17 (9) 2681-2691
    CrossrefPubMedSearch in Google Scholar
  • 17 Aupérin A, Arriagada R, Pignon J P Prophylactic Cranial Irradiation Overview Collaborative Group et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission.  N Engl J Med. 1999;  341 (7) 476-484
    CrossrefPubMedSearch in Google Scholar
  • 18 Arriagada R, Le Chevalier T, Borie F et al.. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission.  J Natl Cancer Inst. 1995;  87 (3) 183-190
    CrossrefPubMedSearch in Google Scholar
  • 19 Patel S, Macdonald O K, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer.  Cancer. 2009;  115 (4) 842-850
    CrossrefPubMedSearch in Google Scholar
  • 20 Slotman B, Faivre-Finn C, Kramer G EORTC Radiation Oncology Group and Lung Cancer Group et al. Prophylactic cranial irradiation in extensive small-cell lung cancer.  N Engl J Med. 2007;  357 (7) 664-672
    CrossrefPubMedSearch in Google Scholar
  • 21 Slotman B J, Mauer M E, Bottomley A et al.. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.  J Clin Oncol. 2009;  27 (1) 78-84
    CrossrefPubMedSearch in Google Scholar
  • 22 Le Péchoux C, Dunant A, Senan S Prophylactic Cranial Irradiation (PCI) Collaborative Group et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.  Lancet Oncol. 2009;  10 (5) 467-474
    CrossrefPubMedSearch in Google Scholar
  • 23 Greco F A, Oldham R K. Clinical management of patients with small cell lung cancer. In: Greco F A, Oldham R K, Bunn P A, eds. Small Cell Lung Cancer. New York: Grune & Stratton; 1981: 353-379
    Search in Google Scholar
  • 24 Lowenbraun S, Bartolucci A, Smalley R V, Lynn M, Krauss S, Durant J R. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma.  Cancer. 1979;  44 (2) 406-413
    CrossrefPubMedSearch in Google Scholar
  • 25 Ihde D C. Chemotherapy of lung cancer.  N Engl J Med. 1992;  327 (20) 1434-1441
    CrossrefPubMedSearch in Google Scholar
  • 26 Evans W K, Shepherd F A, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer.  J Clin Oncol. 1985;  3 (11) 1471-1477
    PubMedSearch in Google Scholar
  • 27 Fukuoka M, Furuse K, Saijo N et al.. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer.  J Natl Cancer Inst. 1991;  83 (12) 855-861
    CrossrefPubMedSearch in Google Scholar
  • 28 Roth B J, Johnson D H, Einhorn L H et al.. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.  J Clin Oncol. 1992;  10 (2) 282-291
    CrossrefPubMedSearch in Google Scholar
  • 29 Sundstrøm S, Bremnes R M, Kaasa S Norwegian Lung Cancer Study Group et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.  J Clin Oncol. 2002;  20 (24) 4665-4672
    CrossrefPubMedSearch in Google Scholar
  • 30 Pujol J L, Carestia L, Daurès J P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent.  Br J Cancer. 2000;  83 (1) 8-15
    CrossrefPubMedSearch in Google Scholar
  • 31 Mascaux C, Paesmans M, Berghmans T European Lung Cancer Working Party (ELCWP) et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.  Lung Cancer. 2000;  30 (1) 23-36
    CrossrefPubMedSearch in Google Scholar
  • 32 Chute J P, Chen T, Feigal E, Simon R, Johnson B E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.  J Clin Oncol. 1999;  17 (6) 1794-1801
    PubMedSearch in Google Scholar
  • 33 Noda K, Nishiwaki Y, Kawahara M Japan Clinical Oncology Group et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.  N Engl J Med. 2002;  346 (2) 85-91
    CrossrefPubMedSearch in Google Scholar
  • 34 Hanna N, Bunn Jr P A, Langer C et al.. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.  J Clin Oncol. 2006;  24 (13) 2038-2043
    CrossrefPubMedSearch in Google Scholar
  • 35 Lara Jr P N, Natale R, Crowley J et al.. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.  J Clin Oncol. 2009;  27 (15) 2530-2535
    CrossrefPubMedSearch in Google Scholar
  • 36 Eckardt J R, von Pawel J, Papai Z et al.. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.  J Clin Oncol. 2006;  24 (13) 2044-2051
    CrossrefPubMedSearch in Google Scholar
  • 37 Thomas P, Castelnau O, Paillotin D et al.. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study.  J Clin Oncol. 2001;  19 (5) 1320-1325
    CrossrefPubMedSearch in Google Scholar
  • 38 Lyss A P, Herndon II J E, Lynch Jr T J et al.. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).  Clin Lung Cancer. 2002;  3 (3) 205-210 discussion 211-212
    CrossrefPubMedSearch in Google Scholar
  • 39 Hanna N H, Einhorn L H. Small-cell lung cancer: state of the art.  Clin Lung Cancer. 2002;  4 (2) 87-94
    CrossrefPubMedSearch in Google Scholar
  • 40 Postmus P E, Berendsen H H, van Zandwijk N, Splinter T A, Burghouts J T, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy.  Eur J Cancer Clin Oncol. 1987;  23 (9) 1409-1411
    CrossrefPubMedSearch in Google Scholar
  • 41 Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer.  Eur J Cancer Clin Oncol. 1987;  23 (11) 1697-1699
    CrossrefPubMedSearch in Google Scholar
  • 42 O'Brien M ER, Ciuleanu T E, Tsekov H et al.. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.  J Clin Oncol. 2006;  24 (34) 5441-5447
    CrossrefPubMedSearch in Google Scholar
  • 43 von Pawel J, Schiller J H, Shepherd F A et al.. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.  J Clin Oncol. 1999;  17 (2) 658-667
    CrossrefPubMedSearch in Google Scholar
  • 44 Yana T, Negoro S, Takada M West Japan Thoracic Oncology Group et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study.  Invest New Drugs. 2007;  25 (3) 253-258
    CrossrefPubMedSearch in Google Scholar
  • 45 Ohe Y, Negoro S, Matsui K et al.. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer.  Ann Oncol. 2005;  16 (3) 430-436
    CrossrefPubMedSearch in Google Scholar
  • 46 Onoda S, Masuda N, Seto T Thoracic Oncology Research Group Study 0301 et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.  J Clin Oncol. 2006;  24 (34) 5448-5453
    CrossrefPubMedSearch in Google Scholar
  • 47 Igawa S, Yamamoto N, Ueda S et al.. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.  J Thorac Oncol. 2007;  2 (8) 741-744
    CrossrefPubMedSearch in Google Scholar
  • 48 Ettinger D S, Jotte R, Lorigan P et al.. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.  J Clin Oncol. 2010;  28 (15) 2598-2603
    CrossrefPubMedSearch in Google Scholar
  • 49 Shimokawa T, Shibuya M, Kitamura K et al.. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer.  Int J Clin Oncol. 2009;  14 (1) 63-69
    CrossrefPubMedSearch in Google Scholar
  • 50 Inoue A, Sugawara S, Yamazaki K et al.. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.  J Clin Oncol. 2008;  26 (33) 5401-5406
    CrossrefPubMedSearch in Google Scholar
  • 51 Eckardt J R, Bentsion D L, Lipatov O N et al.. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.  J Clin Oncol. 2009;  27 (12) 2046-2051
    CrossrefPubMedSearch in Google Scholar
  • 52 Spigel D R, Hainsworth J D, Lane C M, Clark B, Burris H A, Greco F A. Phase II trial of vinflunine in relapsed small cell lung cancer.  J Thorac Oncol. 2010;  5 (6) 874-878
    CrossrefPubMedSearch in Google Scholar
  • 53 Ciuleanu T, Samarzjia M, Demidchik Y et al.. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy.  [abstract 7002] J Clin Oncol. 2010;  28 (15 Suppl) 515s
    CrossrefPubMedSearch in Google Scholar
  • 54 Rudin C M, Hann C L, Peacock C D, Watkins D N. Novel systemic therapies for small cell lung cancer.  J Natl Compr Canc Netw. 2008;  6 (3) 315-322
    PubMedSearch in Google Scholar
  • 55 Skarlos D V, Samantas E, Kosmidis P et al.. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.  Ann Oncol. 1994;  5 (7) 601-607
    CrossrefPubMedSearch in Google Scholar
  • 56 Johnson D H. “The guard dies, it does not surrender!” progress in the management of small-cell lung cancer?.  J Clin Oncol. 2002;  20 (24) 4618-4620
    PubMedSearch in Google Scholar
  • 57 Seifter E J, Ihde D C. Therapy of small cell lung cancer: a perspective on two decades of clinical research.  Semin Oncol. 1988;  15 (3) 278-299
    PubMedSearch in Google Scholar
  • 58 Aisner J, Alberto P, Bitran J et al.. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop.  Cancer Treat Rep. 1983;  67 (1) 37-43
    PubMedSearch in Google Scholar
  • 59 Lassen U N, Hirsch F R, Osterlind K, Bergman B, Dombernowsky P. Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress?.  Lung Cancer. 1998;  20 (3) 151-160
    CrossrefPubMedSearch in Google Scholar

Gregory P KalemkerianM.D. 

Division of Hematology/Oncology, University of Michigan Medical School

1500 E. Medical Center Dr., C350 Med Inn–SPC 5848, Ann Arbor, MI 48109-5848

Email: kalemker@umich.edu